Scholarlink

<p>Lymph node metastasis (LNM) is significantly associated with distant metastasis and poor prognosis in patients with breast cancer (BC). However, the mechanism underlying LNM in BC remains unclear, limiting the development of effective anti-metastatic strategies. Given the lipid-enriched lymphatic microenvironment, we identify the fatty acid transporter cluster of differentiation 36 (CD36) via TCGA-based screening. Aberrant expression of CD36 is positively correlated with LNM and poor prognosis in clinical specimens. BC cells with high expression of CD36 confers anoikis-resistance exposed to lymph or palmitic acid treatment. Furthermore, CD36 drives LNM in both popliteal LNM and orthotopic BC mouse models through yes-associated protein (YAP)-TEADs signaling pathway. Elevated CD36 faciliates the uptake of fatty acids and induces the PPARα-CYP7A1-bile acid biosynthesis pathway, leading to the nucleus translocation and activation of YAP by suppressing the YAP phosphorylation at Ser127. Activated YAP-TEADs complexes directly bind to the <i>BCL2</i> promoter to upregulate Bcl-2 expression. Collectively, our findings identify CD36 as a critical regulator of LNM in BC and reveal a CD36-PPARα-CYP7A1-YAP regulatory axis that may provide an effective therapeutic window for preventing metastasis in BC.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Elevated CD36 drives lymph node metastasis of breast cancer by activating Hippo-YAP signaling-mediated anoikis resistance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月21日

查看全文
  • Zhijian Huang,
  • Xiaoyan Zhang,
  • Jiajia Huang,
  • Xiaojun Liu,
  • Minting Liang,
  • Fengyu Yang,
  • Tianxiao Gao,
  • Jieye Huang,
  • Gan Xia,
  • Jizhao Cao,
  • Jiayin Lu,
  • Ti Zhou,
  • Weiwei Qi,
  • Anton Gao,
  • Guoquan Gao,
  • Xia Yang

摘要

Lymph node metastasis (LNM) is significantly associated with distant metastasis and poor prognosis in patients with breast cancer (BC). However, the mechanism underlying LNM in BC remains unclear, limiting the development of effective anti-metastatic strategies. Given the lipid-enriched lymphatic microenvironment, we identify the fatty acid transporter cluster of differentiation 36 (CD36) via TCGA-based screening. Aberrant expression of CD36 is positively correlated with LNM and poor prognosis in clinical specimens. BC cells with high expression of CD36 confers anoikis-resistance exposed to lymph or palmitic acid treatment. Furthermore, CD36 drives LNM in both popliteal LNM and orthotopic BC mouse models through yes-associated protein (YAP)-TEADs signaling pathway. Elevated CD36 faciliates the uptake of fatty acids and induces the PPARα-CYP7A1-bile acid biosynthesis pathway, leading to the nucleus translocation and activation of YAP by suppressing the YAP phosphorylation at Ser127. Activated YAP-TEADs complexes directly bind to the BCL2 promoter to upregulate Bcl-2 expression. Collectively, our findings identify CD36 as a critical regulator of LNM in BC and reveal a CD36-PPARα-CYP7A1-YAP regulatory axis that may provide an effective therapeutic window for preventing metastasis in BC.